The purpose of this study was to use serial venous duplex scans to document the status of deep venous thrombi during the early phase of therapy for acute, deep-vein thrombosis (DVT). A total of 71 consecutive participants treated for a first episode of acute DVT were monitored for new venous thrombosis using serial venous duplex scans. An average of 4.6 duplex scans were performed per patient (range, three to seven) during the 3-week study period. The cumulative incidence of contiguous/non-contiguous extension of the DVT at 3 weeks was 26% (95% CI = 14% to 38%). Nine of the 15 (60%) occurrences were asymptomatic. None of the classical risk factors for DVT was significantly associated with the development of new thrombi. The fraction of time during which the level of anticoagulation was considered 'adequate' (international normalized ratio у2.0 and/or heparin concentration у0.2 IU/ml) was inversely associated with the risk of extension/new thrombi (p = 0.01, Cox proportional hazards analysis).
Introduction
One of the goals of therapy for acute, deep-vein thrombosis (DVT) is to stabilize the thrombi that have developed to prevent further damage to the deep venous system and hopefully minimize the development of the post-thrombotic syndrome. Several recent prospective clinical trials have sought to determine the optimal intensity, duration and formulation of anticoagulant drugs used for the treatment of DVT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Recurrent thrombosis in these trials has been documented using either venography, plethysmography, or 125 I-labeled fibrinogen scanning. In many studies, these follow-up diagnostic tests were performed either infrequently [1] [2] [3] [4] [5] [6] [7] or only when the patients became symptomatic. [8] [9] [10] Of these diagnostic modalities, the only method that can reliably examine the location and extent of the thrombi is venography. However, this test cannot be used to document over time the changes that occur during therapy.
Natural history studies based on serial duplex scanning of patients with acute DVT have established that lower extremity venous thrombi are dynamic structures, especially during the first few weeks after the initial diagnosis. [11] [12] [13] [14] Clot retraction, lysis and extension are frequent occurrences and may not lead to new symptoms. Thus, the reliable detection of recurrent lower extremity thrombosis requires a diagnostic test that is both accurate and noninvasive so that it can be performed frequently during follow-up.
Most diagnostic methods short of venography have demonstrated marginal sensitivity for detecting venous thrombosis. [15] [16] [17] [18] [19] [20] [21] [22] In contrast, venous duplex scanning is both sensitive and specific. [23] [24] [25] [26] [27] [28] [29] It can be used for the repetitive study of the fate of venous thrombi at any time during and after completion of therapy and therefore is an effective tool for the prospective assessment of the status of lower extremity venous thrombosis and its effects on long-term venous function.
The goals of this study were to use serial duplex scanning to document the incidence of early contiguous and non-contiguous extension of thrombi of the lower extremity veins after acute DVT in a tertiary care center, and to assess the significance of the level of anticoagulation and the presence of other risk factors for DVT on the subsequent risk of further extension.
Methods
A prospective study designed to assess the incidence of and risk factors for recurrent thrombosis in patients with a first diagnosis of acute DVT was begun in September 1994. Patients were excluded from participating in this study if they had a prior history of DVT or if they had evidence of chronic venous stasis disease or post-thrombotic changes that were apparent clinically or from the baseline duplex examination. All participants were treated for their DVT at the University of Washington Medical Center.
This study was approved by the Human Subjects Review Committee at the University of Washington and informed consent was obtained from all subjects.
Participants were seen in the Vascular Research Laboratory at approximately 1, 3, 7, 14 and 21 days after the initial diagnosis of acute DVT. A brief history and physical examination were performed prior to each duplex examination. Patients were questioned regarding the presence of known risk factors for DVT, including the presence of malignancy, congestive heart failure, pregnancy, a history of recent surgery, prolonged bed rest, recent travel, the use of oral contraceptive pills, or a family history of DVT. The presence of lower extremity pain and swelling and the occurrence of both major and minor hemorrhagic complications resulting from anticoagulant therapy was also assessed.
The technique of lower extremity venous duplex scanning has been described in detail elsewhere. 23, 30 Duplex scans were performed with an Ultramark 9 duplex scanner (Advanced Technology Laboratories, Bothell, WA, USA). At each examination, both lower extremities were scanned from the inferior vena cava to the ankle. Thrombosis worsening (contiguous/non-contiguous) was defined as either non-occlusive or occlusive thrombosis of a venous segment that was not involved at the baseline examination, or complete occlusion of a partially occluded segment at baseline. Non-occlusive thrombosis is defined as the presence of flow in an incompletely compressible vessel, with or without visible thrombus. Occlusive thrombosis is the absence of flow in an incompressible vessel.
All thromboses (baseline and new) were categorized by their venous location as follows: 'ileofemoral' = thrombosis of the inferior vena cava, iliac veins and/or common femoral vein; 'femoropopliteal' = thrombosis of the profunda femoris, superficial femoral and/or popliteal veins; 'proximal' = femoropopliteal and/or ileofemoral thrombosis; and 'calf vein' = thrombosis of the soleal sinuses, gastrocnemius, posterior tibial and/or peroneal veins. The anterior tibial veins were not assessed. Recurrent thromboses were also categorized as either contiguous with or not contiguous with the baseline venous thrombus.
It was possible to image successfully the iliac veins during 82% of all examinations. During the remaining 18% of examinations, determination of the iliac vein status was based on the phasicity of flow in the common femoral vein and the effect of Valsalva's and manual compression maneuvers. It was possible to image the femoropopliteal and tibial segments nearly 100% of the time. The two exceptions were patients who had orthopedic surgical procedures and immobilizing devices placed, which precluded complete examination during two visits for each patient.
All aspects of patient care were managed by the primary treating physicians, including anticoagulant dosing and laboratory assessment. The level of anticoagulation was monitored by accessing the hospital laboratory data base. Knowledge of a patient's level of anticoagulation did not influence treatment because the research staff were not involved in patient care. An 'adequate' level of anticoagulation was defined in accordance with currently accepted guidelines 31, 32 : (1) INR and PTT of each patient were plotted as a function of time with linear interpolation between the data points, and the then proportion of time during which the level of anticoagulation was greater than or equal to this threshold value was calculated.
The decision to perform diagnostic tests to document the occurrence of pulmonary embolus was also made entirely by the patients' primary treating physicians. For this analysis, all pulmonary emboli were documented with either a positive pulmonary angiogram or a 'high-probability' ventilation-perfusion lung scan.
Statistical analysis
The data analysis was performed using SPSS for Windows, version 6.1. The cumulative incidence of new lower extremity venous thrombosis during the first 3 weeks of treatment for acute DVT was estimated using the Kaplan-Meier method. Survival methods were used because there was considerable censoring, due to the variable time to the last duplex examination performed within the 21-day study period. The time to detection of the new problem for participants above versus below the median level of anticoagulation was compared and the statistical significance was assessed using the log rank test. Other risk factors for recurrent thrombosis were assessed and adjustment for baseline covariates was performed using the Cox proportional hazards model.
Results
A total of 71 patients were recruited into this prospective study between September 1994 and December 1996. All patients had between three and seven duplex examinations during the 3-week study period. The median length of follow-up in this study was 15 days (range, 2 to 21 days), with 'follow-up' defined as the number of days from the baseline examination to the last duplex examination performed within the 3-week study period.
The characteristics of this patient population are listed in Table 1 . Some 53 patients (75%) presented with lower extremity symptoms and 13 (18%) presented with symptomatic pulmonary emboli. A total of 13 patients (18%) had isolated calf vein thromboses (the remainder had proximal DVT), and 31 (44%) had ileofemoral involvement. Four patients (6%) did not receive either heparin or coumadin: three of these patients had isolated calf vein thromboses and one patient had a contraindication to anticoagulation and was treated with a vena cava filter. None of the patients in this study was treated with low-molecular-weight heparin during the study period. Table 2 lists the characteristics of the thromboembolic complications detected in this study. New, lower extremity venous thrombosis was detected in 15 of the 71 (21%) patients during the study period. The Kaplan-Meier estimate of the cumulative incidence of this new event is shown in Figure 1 . The figure demonstrates that the risk was particularly high during the first week after the diagnosis of acute DVT and then leveled off after 2 weeks. The cumulative incidence of new thrombosis was 13% at 5 days and 26% by 3 weeks. Nine of 15 (60%) of these events were asymptomatic and 13 of 15 (87%) by 3 weeks. A total of 13 of 15 recurrences involved iliac, femoral and/or popliteal venous segments: two were calf vein recurrences. Five of 15 (33%) the new events were at sites that were non-contiguous with the baseline thrombus: three of these occurred in initially uninvolved legs. Pulmonary emboli were documented in two patients (3%) during the study period, and one of these events was fatal. New venous thromboses were detected in both of these patients in the iliac and femoral veins at approximately the same time that the pulmonary emboli were documented.
There were no major hemorrhagic complications Vascular Medicine 1999; 4: 9-14 resulting from anticoagulant therapy in this study. There was only one minor hemorrhagic complication: a small thigh hematoma that developed in a patient who had undergone hip replacement. The results of a Cox regression analysis of potential risk factors for the development of new thrombi are shown in Table 3 . Increasing age, female gender and a history of recent surgery were associated with moderate, but statistically insignificant increases in the risk of new thromboses. Surprisingly, a recent diagnosis of malignancy and a recent history of prolonged bed rest were associated with decreased (although statistically insignificant) risk. The risk of new events among patients with a proximal baseline DVT was slightly higher than those with isolated calf vein thrombosis, but this difference was not significant. Figure 2 shows the distribution of the percentage of time that anticoagulation was deemed 'adequate' (INR у2.0 and/or heparin concentration у0.2 IU/ml) among the 71 study subjects. The median value was 80%. Patients who were adequately anticoagulated р20% of the time were either not anticoagulated at all (n = 4) or were not anticoagulated aggressively.
The only factor that showed a statistically significant association with the risk of new thrombi developing was the level of anticoagulation achieved ( Table 3 , lower half). Each 20% reduction in the percentage of time anticoagulation that was 'adequate' was associated with a 1.4-fold increase in the risk of new thrombi developing (p = 0.01). This association persisted among the patients who received anticoagulant therapy (n = 67) and was not affected by adjustment for age, gender, malignancy, recent surgery, or a history of prolonged bed rest. Figure 3 shows the Kaplan-Meier plots for patients who were adequately anticoagulated у80% versus Ͻ80% of the time. The 3-week cumulative incidence of new venous thrombosis was 14% and 38% for patients with adequate levels of anticoagulation у80% and Ͻ80% of the study period, respectively.
Discussion
There are two striking findings in this study. First, the incidence of detectable new thromboses during the first 3 weeks of therapy for acute DVT was high. Secondly, the level of anticoagulation achieved was frequently inadequate.
A number of randomized prospective trials have been conducted using recurrent venous thromboembolism as the primary endpoint, and the incidence of recurrent DVT in these trials has not been as high as in this prospective observational study. For example, in a trial comparing intravenous with subcutaneous heparin for the treatment of acute DVT, the 3-month cumulative incidence of recurrent thromboembolism was 5% and 19% in the intravenous and subcutaneous groups respectively. 3 In another trial that evaluated intravenous heparin therapy for 5 days compared with 10 days, the 3-month cumulative incidence of recurrent thromboembolism was 7% in both groups. 1 In a third trial comparing 4 weeks versus 3 months of coumadin therapy, recurrent thromboembolism occurred in 9% and 1% of patients' respectively, by 2 months. 4 These figures are considerably lower than the 26% of patients suffering This discrepancy in recurrence rates is in large part due to the study methods that were used. In several studies, objective testing for recurrent thrombosis was performed only after the development of new symptoms during follow-up. [8] [9] [10] Yet, this present study demonstrates that the majority of recurrences occur without the development of new symptoms. In several other studies, objective testing was performed infrequently using impedance plethysmography (IPG) Ϯ 125 I-labeled fibrinogen scanning (IFS) as a screening test for asymptomatic patients. [1] [2] [3] [4] [5] [6] [7] However, the Vascular Medicine 1999; 4: 9-14 sensitivity of both IPG and IFS for detecting deep-vein thrombosis in asymptomatic patients is poor, [17] [18] [19] [20] [21] [22] and the sensitivity of these tests for detecting recurrent thrombosis may be even worse. For example, a new thrombosis that is non-occlusive and/or located in the calf veins or within the same flow channel as the baseline thrombus is not likely to result in a significant change in the obstruction to venous outflow and may not be detectable by IPG. Similarly, small recurrences that are contiguous with the baseline thrombus or separated in time from the time of diagnostic testing may not be detectable by IFS.
The sensitivity of duplex scanning, on the other hand, has ranged between 90% and 100% when compared with venography, especially when performed with color-flow capability and in centers of excellence. [23] [24] [25] [26] [27] [28] [29] When duplex scanning was used to document recurrent thrombosis in patients receiving heparin therapy for acute DVT, Krupski et al found a 38% recurrence rate within the acute period 30 -a figure that is more in accord with the cumulative incidence of recurrence observed in this study.
A second reason why the incidence of recurrent lower extremity venous thrombosis was high in this study is that the level of anticoagulation achieved was frequently inadequate. This study confirms the relative efficacy of currently recommended anticoagulation levels, but it also confirms that these levels are frequently not attained in clinical practice during the acute phase of treatment. Similarly, Wheeler et al found that 60% of patients treated with heparin did not have a single PTT greater than 1.5 times control during the first 24 h of heparin therapy. 31 Because the incidence of serious hemorrhagic complications observed in this study was negligible, it is possible that many of the recurrent thromboses observed could have been avoided by more aggressive anticoagulation.
The incidence of recurrent thrombosis in this study was particularly high during the first half of the study period. This finding is consistent with the hypothesis that adequate levels of anticoagulation are often not achieved when heparin is first started and when patients are being switched from heparin to coumadin therapy.
The long-term clinical course of patients with a first episode of DVT was recently studied by Prandoni and associates. 32 Some 245 of 355 patients completed 5 years of follow-up. An important finding from that study was that ipsilateral recurrent DVT was associated with an increased risk for the post-thrombotic syndrome (hazard ratio = 6.4, 95% CI = 3.1-13.3). Previous studies by the present authors have demonstrated that the development of venous valvular reflux is significantly more common among extremities with recurrence, regardless of whether the recurrent event is associated with new symptoms. 13 It is therefore reasonable to expect that the risk of the post-thrombotic syndrome Vascular Medicine 1999; 4: 9-14 is elevated in both symptomatic and asymptomatic patients with new thromboses or extension of existing thrombi.
Summary
It has been demonstrated here that recurrent venous thrombosis is a frequent occurrence during the first 3 weeks following a diagnosis of acute DVT. The majority of these events occur without new acute symptoms. The higher rates of recurrence reported here (in contrast with other published reports) are probably related both to the higher sensitivity of duplex scanning for detecting asymptomatic events and to the inadequate levels of anticoagulation achieved in this non-clinical trial setting. Given that asymptomatic, recurrent lower extremity venous thrombosis is a frequent and clinically important occurrence, its detection in large randomized trials designed to determine the optimal intensity, duration and formulation of anticoagulant therapy for patients with acute DVT is crucial. Because of its noninvasive nature and its accuracy and anatomic specificity, duplex scanning is the preferred modality for this purpose.
